Thermaquil

Thermaquil is a private medical device company developing reversible, drug-free nerve block technologies for pain management and other disorders driven by overactive nerves. The company originated from University of Pittsburgh research and is focused on non-invasive or minimally invasive thermal neuromodulation devices that temporarily block nerve signaling without drugs or electrical stimulation. Its lead development efforts have included a non-invasive occipital nerve block device for chronic migraine and headaches, as well as programs for postoperative pain and bladder function restoration in spinal cord injury. Thermaquil appears to operate as a platform neurotechnology company applying a common thermal nerve block mechanism across multiple peripheral nerve indications. The company has been funded primarily through grants, including NIH, NSF, and DARPA-associated support, and remains privately held.